Clinical utility of circulating calprotectin to assist prediction and monitoring of COVID-19 severity : An Italian study
© 2022 Wiley Periodicals LLC..
BACKGROUND: Calprotectin (S100A8/A9) has been identified as a biomarker that can aid in predicting the severity of disease in COVID-19 patients. This study aims to evaluate the correlation between levels of circulating calprotectin (cCP) and the severity of COVID-19.
METHODS: Sera from 245 COVID-19 patients and 110 apparently healthy individuals were tested for calprotectin levels using a chemiluminescent immunoassay (Inova Diagnostics). Intensive care unit (ICU) admission and type of respiratory support administered were used as indicators of disease severity, and their correlation with calprotectin levels was assessed.
RESULTS: Samples from patients in the ICU had a median calprotectin concentration of 11.6 µg/ml as compared to 3.5 µg/ml from COVID-19 patients who were not in the ICU. The median calprotectin concentration in a cohort of healthy individuals collected before the COVID-19 pandemic was 3.0 µg/ml (95% CI: 2.820-2.969 µg/ml). Patients requiring a Venturi mask, continuous positive airway pressure, or orotracheal intubation all had significantly higher values of calprotectin than controls, with the increase of cCP levels proportional to the increasing need of respiratory support.
CONCLUSION: Calprotectin levels in serum correlate well with disease severity and represent a promising serological biomarker for the risk assessment of COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:94 |
|---|---|
| Enthalten in: |
Journal of medical virology - 94(2022), 12 vom: 09. Dez., Seite 5758-5765 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Infantino, Maria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 17.10.2022 Date Revised 05.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.28056 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344605094 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344605094 | ||
| 003 | DE-627 | ||
| 005 | 20231226023147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.28056 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344605094 | ||
| 035 | |a (NLM)35941084 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Infantino, Maria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical utility of circulating calprotectin to assist prediction and monitoring of COVID-19 severity |b An Italian study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.10.2022 | ||
| 500 | |a Date Revised 05.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: Calprotectin (S100A8/A9) has been identified as a biomarker that can aid in predicting the severity of disease in COVID-19 patients. This study aims to evaluate the correlation between levels of circulating calprotectin (cCP) and the severity of COVID-19 | ||
| 520 | |a METHODS: Sera from 245 COVID-19 patients and 110 apparently healthy individuals were tested for calprotectin levels using a chemiluminescent immunoassay (Inova Diagnostics). Intensive care unit (ICU) admission and type of respiratory support administered were used as indicators of disease severity, and their correlation with calprotectin levels was assessed | ||
| 520 | |a RESULTS: Samples from patients in the ICU had a median calprotectin concentration of 11.6 µg/ml as compared to 3.5 µg/ml from COVID-19 patients who were not in the ICU. The median calprotectin concentration in a cohort of healthy individuals collected before the COVID-19 pandemic was 3.0 µg/ml (95% CI: 2.820-2.969 µg/ml). Patients requiring a Venturi mask, continuous positive airway pressure, or orotracheal intubation all had significantly higher values of calprotectin than controls, with the increase of cCP levels proportional to the increasing need of respiratory support | ||
| 520 | |a CONCLUSION: Calprotectin levels in serum correlate well with disease severity and represent a promising serological biomarker for the risk assessment of COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a ICU | |
| 650 | 4 | |a circulating calprotectin | |
| 650 | 4 | |a respiratory support | |
| 650 | 4 | |a risk assessment | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Calgranulin A |2 NLM | |
| 650 | 7 | |a Leukocyte L1 Antigen Complex |2 NLM | |
| 700 | 1 | |a Manfredi, Mariangela |e verfasserin |4 aut | |
| 700 | 1 | |a Alessio, Maria Grazia |e verfasserin |4 aut | |
| 700 | 1 | |a Previtali, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Grossi, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Benucci, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Faraone, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Fortini, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Grifoni, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Masotti, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Edda |e verfasserin |4 aut | |
| 700 | 1 | |a Amedei, Amedeo |e verfasserin |4 aut | |
| 700 | 1 | |a FitzGerald, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Albesa, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Norman, Gary L |e verfasserin |4 aut | |
| 700 | 1 | |a Mahler, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 94(2022), 12 vom: 09. Dez., Seite 5758-5765 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:94 |g year:2022 |g number:12 |g day:09 |g month:12 |g pages:5758-5765 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.28056 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 94 |j 2022 |e 12 |b 09 |c 12 |h 5758-5765 | ||